General discussion, page-1654

I personally hold BOT as well, I invested in them mainly due to their trial into antimicrobial resistance. A result trial they undertook demonstrated that when their treatment is applied to human skin it completely eliminates resistant Staphylococcus aureus (Golden Staph). Super bugs such as Golden Staph cause over 700,000 deaths globally every year. So if BOT can demonstrate that their formula works it'll be huge.
They are currently in a phase two trial with results due in a little bit over a month so no wonder it's starting to take off.
Interesting to watch its SP take off just on anticipation for the results of this trial though. Goes to show how quickly these sort of companies can multiply in SP, we for example have two trials happening and are generating revenue and were half their market cap.
Its good to see other biotechs and MM companies heading upwards after such a long time stagnated I think this all bodes well for the entire sector.